BiotechTubeBiotechTube
Home/X4 Pharmaceuticals/David Kirske
DK

David Kirske

Chief Financial Officer

X4 Pharmaceuticals

Therapeutic Areas

Rare DiseasesImmunologyHematology

X4 Pharmaceuticals Pipeline

DrugIndicationPhase
XOLREMDI® (mavorixafor)WHIM syndrome (patients 12 years and older)Approved
MavorixaforChronic Neutropenic DisordersPhase 3

Leadership Team at X4 Pharmaceuticals

AC
Adam Craig, MD, PhD, MBA
Executive Chair
JV
John Volpone
President, Chief Operating Officer
GJ
Gary J. Bridger, PhD
Board of Directors
View full X4 Pharmaceuticals profile